What Летрозол Treats: Main Uses and Benefits

Летрозол is commonly used in the management of estrogen receptor-positive breast cancer in postmenopausal women. The medication is applied in addressing conditions marked by increased physiological stress, generally contributing to easing the overall symptom load in both early-stage and metastatic settings. This is relevant across clinical settings that involve acute or disruptive symptom patterns, and may include conditions such as adjuvant therapy after primary treatment, extended adjuvant therapy following other hormonal agents, and as a first-line agent for locally advanced or metastatic disease. This application helps address the potential for residual disease to recur years later, and contributes to reducing the risk of cancer recurrence, which may assist with maintaining functional stability following primary therapy.

In advanced cases, it assists with managing symptoms that create noticeable physiological strain. This provides support that helps ease the overall symptom burden and contributes to easing the overall symptom load related to disease activity.

“The medication supports the patient during difficult episodes by easing distress and managing the symptomatic domains of the condition.”

---

Quick Fact: Relief for Conditions Characterized by Periods of Heightened Symptoms

• Target Conditions: Estrogen receptor-positive breast cancer (early-stage, advanced, metastatic).
• Core Benefit: Contributes to reducing the risk of cancer relapse and contributes to easing the overall symptom load related to disease activity.
• Scenario: Long-term supportive management following primary treatment.

Who Can and Cannot Use Летрозол?

Official eligibility for Letrozole is strictly defined by regulatory documents, focusing primarily on a patient's hormonal and reproductive status.

---

Populations Permitted for Standard Use

This medicine is approved for use in postmenopausal women with confirmed endocrine status. Adult and elderly patients (65 years of age or older) are eligible and typically require no dosage adjustment based on age alone. Patients with mild to moderate hepatic impairment or non-severe renal impairment (Creatinine Clearance ge 10 mL/min) are generally permitted to use the medicine.

---

Absolute Contraindications

Letrozole is contraindicated and must not be used in several populations. These include pregnant women (due to classified fetal risk), women of premenopausal endocrine status, and women who are breastfeeding or lactating. Individuals with a known hypersensitivity (allergic reaction) to the drug or its excipients are also ineligible.

---

Conditional and Restricted Use

Use is restricted in patients with severe hepatic impairment (Child-Pugh C), who require close supervision and a dose reduction. The drug is not recommended for the pediatric population (children and adolescents), as safety and efficacy have not been established. Patients with severe renal impairment (CrCl <10 mL/min) are cautioned, as there is insufficient regulatory data to establish safe use.

Interactions with other medicines and products

Product Category	Interacting Medicine (Examples)	Interaction Note
Estrogens/Anti-estrogens	Tamoxifen, Hormone Replacement Therapy (HRT)	Concomitant use with estrogen-containing drugs is generally avoided as it may diminish Letrozol's pharmacological effect. Co-administration with Tamoxifen has been shown to reduce Letrozol plasma levels by about 38% on average, though clinical experience suggests the therapeutic effect may not be impaired when administered sequentially.
Enzyme Modifiers (CYP)	Phenytoin, Rifampicin, Carbamazepine, Phenobarbital, St. John's Wort	These strong CYP3A4 inducers may decrease Letrozol plasma concentrations and reduce its effectiveness. Caution is advised.
	Ketoconazole, Itraconazole, Voriconazole, Ritonavir, Clarithromycin	These strong CYP3A4 and/or CYP2A6 inhibitors may increase Letrozol plasma concentrations, potentially increasing the risk of adverse effects. Caution is advised.

Letrozol is primarily cleared by hepatic metabolism involving the cytochrome P450 isoenzymes CYP2A6 and CYP3A4. In vitro data also indicates that Letrozol is a potent inhibitor of CYP2A6 and a moderate inhibitor of CYP2C19. Therefore, caution is indicated when co-administering Letrozol with medicines that have a narrow therapeutic index and whose elimination largely depends on CYP2C19 (e.g., Phenytoin, Clopidogrel). However, clinical studies with Warfarin and Cimetidine have not demonstrated clinically significant pharmacokinetic interactions.

The mechanism of action for Летрозол (Letrozole) is defined by its specific intervention in the body's hormone synthesis pathways, leading to systemic estrogen depletion. The drug acts at the molecular level with precision, without significantly disrupting the biosynthesis of other adrenal steroids.

---

Targeted Inhibition of Aromatase

The core interaction involves the aromatase enzyme (CYP19), which is the single biological target responsible for the final stage of estrogen production. Летрозол is a selective, nonsteroidal inhibitor that achieves a competitive and reversible blockade by binding directly to the enzyme’s active site. This targeted inhibition functionally blocks the conversion of androgen precursor hormones into estrogens (like estradiol), forming the first step in the mechanistic cascade.

---

Suppression of Peripheral Estrogen

The molecular blockade of the enzyme leads to a cascading effect, primarily impacting estrogen synthesis in peripheral tissues such as body fat, which are the main source of estrogen production outside the ovaries. This action results in a marked and sustained reduction in the systemic concentration of circulating estrogen throughout the body. The decrease in estrogen then triggers a compensatory rise in pituitary Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), a direct physiological consequence of the removed estrogenic feedback.

Letrozole is administered orally in the form of a 2.5 mg film-coated tablet as a fixed daily dose for all approved contexts. The medication is taken once a day to ensure continuous systemic exposure. Standard instructions indicate that the tablet should be swallowed whole and should not be crushed, chewed, or halved to preserve its intended administration profile. Patients are instructed to take the dose at approximately the same time each day, and it can be taken with or without food.

---

Usage Pattern	Standard Regimen	Course Duration
Daily Dose	2.5 mg	Continuous daily use
Adjuvant Setting	2.5 mg once daily	Up to 5 years or until tumor relapse
Advanced Disease	2.5 mg once daily	Continued until tumor progression is evident

---

For certain patient populations, specific high-level modifications to the standard regimen are defined. In cases of severe hepatic impairment (Child-Pugh C), the recommended dose is adjusted to 2.5 mg administered every other day. No dosage adjustment is required for older adults or for individuals with renal impairment when creatinine clearance is ge 10 mL/min. If a dose is missed, it should be taken as soon as the patient remembers; however, if the time for the next scheduled dose is approaching (e.g., within 2 or 3 hours), the missed dose should be skipped to prevent doubling the daily intake.

Research Evidence / Overview of Studies for Летрозол

This section provides an overview of the types of research and studies that have been conducted on Letrozole. These findings describe group patterns observed in studies and do not provide individual predictions about personal outcomes.

---

Evidence for Extended Adjuvant Treatment

Clinical data for this use originate from large, international randomized, placebo-controlled trials (such as the MA.17 study) involving postmenopausal women who had completed approximately five years of initial hormonal therapy. Researchers primarily monitored how long the women remained free of cancer recurrence (Disease-Free Survival, or DFS) and the occurrence of cancer in the opposite breast (contralateral breast cancer).

Studies reported that the use of Letrozole was associated with observed patterns in DFS and a reduced frequency of contralateral breast cancer over the study period, when compared to the placebo control group. Analyses of Overall Survival (OS) have shown varying findings, with some subgroup analyses describing a pattern, while other analyses found no consistent pattern in the overall study population.

---

Evidence in the Advanced/Metastatic Setting

First-Line Use

Randomized Phase III trials compared Letrozole against older standard hormonal treatments, such as Tamoxifen, in postmenopausal women with advanced hormone receptor-positive disease. The studies measured the time until the cancer began to grow again (Time to Progression, or TTP), the degree of tumor shrinkage (Objective Response Rate, or ORR), and Overall Survival (OS).

Studies reported that measurements of TTP were observed to be increased, and the Objective Response Rate was more frequent, when comparing the Letrozole group to the older comparator drug group. Later long-term follow-up analyses reported no consistent measurable difference in OS between the two agents.

Following Prior Hormonal Therapy Failure

Letrozole was studied for use in patients whose advanced disease had progressed while receiving prior antiestrogen therapy. Trials reported that the frequency of tumor response (Objective Response Rate) was observed to be more frequent with Letrozole compared to certain older second-line comparator agents.

---

Research Limitations and Uncertainty

Several research limitations are noted in the available evidence. A key gap is the limited information for long-term outcomes regarding Overall Survival in the extended adjuvant setting due to early unblinding and subsequent patient crossover in a major trial. The optimal treatment duration—whether longer or shorter than the studied five years—remains an area for further research based on existing data. Results apply only to the populations studied, leaving room for ongoing research to define outcomes in diverse patient subgroups.

Common questions about Летрозол (FAQ)

Q: How is Летрозол different from Тамоксифен?

A: Летрозол and Тамоксифен belong to different classes of hormonal therapy. Летрозол is an aromatase inhibitor that works by significantly reducing the amount of estrogen in the body. Тамоксифен, on the other hand, is a Selective Estrogen Receptor Modulator (SERM) that works primarily by blocking the effects of estrogen on certain cells. Regulatory studies have been conducted to compare the effects and use of these two agents.

---

Q: What is the typical length of time someone stays on Летрозол?

A: The length of treatment varies depending on the specific context of use. For use after initial therapy (adjuvant treatment), major studies show a typical duration of five years. If used for advanced disease, official product information indicates that the treatment generally continues until there are signs that the disease has progressed.

---

Q: Can men use Летрозол, and for what conditions?

A: The official regulatory indications for Летрозол primarily apply to postmenopausal women. However, regulatory review documents for some combination regimens have addressed its use in men for treating hormone receptor-positive advanced breast cancer. Information regarding its use is based on the prescribing information defined in regulatory contexts.

---

Q: Can I take pain relievers like Paracetamol while on Летрозол?

A: Official drug interaction summaries do not typically indicate a clinically significant interaction between Летрозол and Paracetamol (acetaminophen). Since the liver is the primary site for clearing Летрозол, official guidance suggests caution when taking any new medication. Patients are generally advised to discuss all medications, including non-prescription pain relievers, with a healthcare professional.

---

Q: Does alcohol interact with Летрозол?

A: Official regulatory evidence does not suggest a significant or harmful interaction between alcohol and Летрозол. Regulatory sources generally focus on drug-drug interactions. While official safety documents do not list a significant interaction, it is generally noted that alcohol consumption may impact some common side effects.

---

Q: Does Летрозол affect my liver function?

A: Летрозол is metabolized by the liver. Regulatory documents list rare instances of changes to liver function, including hepatitis, as an adverse reaction. For individuals with existing severe hepatic impairment (a serious liver condition), a reduction in the standard dose is recommended by regulatory authorities. Monitoring of liver function may be recommended during treatment, according to regulatory guidelines.

---

Q: Can I travel while taking Летрозол?

A: Regulatory information focuses on the conditions of use and storage, not permission for travel. Official administration instructions emphasize taking the dose at approximately the same time each day, which should be maintained across time zones. Additionally, the medicine must be stored at a controlled room temperature (between 20 C and 25 C) and kept in its original packaging.

---

Q: Is there a link between Летрозол and bone thinning or osteoporosis?

A: Regulatory documents describe a link between the use of Летрозол and the risk of osteoporosis (bone thinning) and an increased occurrence of bone fractures. Due to the mechanism of lowering estrogen, which affects bone health, regulatory labels specifically recommend monitoring Bone Mineral Density (BMD) during the course of treatment.

---

Q: What is the difference between an aromatase inhibitor and other endocrine therapies?

A: Летрозол is a selective aromatase inhibitor that specifically blocks the enzyme responsible for estrogen production, thereby reducing the amount of estrogen in the body. This mechanism is different from other endocrine therapies, such as SERMs (like Тамоксифен) which block the effects of estrogen, or other drugs (like GnRH agonists) which suppress hormone production from the ovaries.

---

Q: Why is Летрозол prescribed for some pre-menopausal women?

A: Летрозол is contraindicated for use as a single agent in women who have not yet reached menopause. This single-agent use is avoided due to the classification of potential fetal harm. Its use in this population is only defined in regulatory contexts when combined with another drug that suppresses ovarian function.

---

Q: Can I take contraceptives while on Летрозол?

A: Official safety documents state that women who are of reproductive potential must use effective non-hormonal contraception during treatment and for a specified time after the final dose. Estrogen-containing medications, which include many hormonal contraceptives, are generally avoided because they may interfere with the drug's intended mechanism of reducing estrogen levels.

---

Q: How quickly does Летрозол start to work?

A: Regulatory studies show that Летрозол is absorbed quickly after taking a dose. Near-maximal suppression of circulating estrogen levels is observed within the first two to four days of treatment. However, it typically takes about two months of continuous daily use for the drug to reach a stable concentration in the bloodstream.

---

Q: Does the dose of Летрозол change over time?

A: For its labeled use in cancer treatment, the standard daily dose is a fixed 2.5 mg tablet. Regulatory documents indicate that this standard dose does not change based on the length of treatment. The only recommended dose modification is a reduction for patients with severe hepatic impairment (serious liver problems).

---

Q: Does Летрозол affect a person's sex drive?

A: Official safety documents list a decrease in libido (sex drive) as a possible adverse reaction. This is generally classified as a common side effect, meaning it may affect between 1% and less than 10% of patients in studies.

---

Q: Is it true that taking Летрозол can affect eyesight?

A: Official adverse reaction lists include rare reports of effects on the eyes. Cataracts are listed as a common side effect, and other less common reported effects include blurred vision. Official guidance emphasizes that any changes in vision should be discussed with a healthcare professional.

---

Q: What should I do if I experience mood changes while on Летрозол?

A: Official safety documents list low mood (including depression) and anxiety as possible side effects. Official guidance notes that if a patient experiences changes in mood, they should discuss these symptoms with a healthcare professional for proper evaluation.

How to Store and Dispose of Letrozole

Letrozole tablets must be stored at a controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be kept in its original package for protection and stored strictly out of the sight and reach of children to prevent accidental ingestion.

---

Disposal Requirements

Official regulatory guidelines state that this medicine must not be disposed of in household waste or wastewater. Unused or expired Letrozole should be discarded by following local regulations or by returning it to a pharmacist or designated collection point.